Are neurologists really data driven in selecting epilepsy treatment?

Neurology

Volumn 78, Issue 16, 2012, Pages 1194-1195

  Labiner, David M ^a   Cascino, Gregory D ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; FOSPHENYTOIN SODIUM; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN;

DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EPILEPSY; EVIDENCE BASED MEDICINE; FOCAL EPILEPSY; HUMAN; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL SCHOOL; MEDICAL STUDENT; NEUROLOGIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEIZURE; TEMPORAL LOBECTOMY; VAGUS NERVE STIMULATION;

EID: 84860713034     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318250d86b     Document Type: Editorial

References (12)

1. The Evidence-based Medicine Toolkit. Available at: Www. aan.com/education/ebm/. Accessed on February 27, 2012.
2. Meek PD, Davis SN, Collins DM, et al. Guidelines for the nonemergency use of parenteral phenytoin products: Proceedings of an expert panel consensus process. Arch Intern Med 1999;159:2639-2644.
3. Labiner DM. Data vs opinion, phenytoin vs fosphenytoin: The saga continues. Arch Intern Med 1999;159:2631-2632.
4. American Academy of Neurology. Clinical Practice Guideline Process Manual, 2011 ed. St. Paul, MN: The American Academy of Neurology. Available at: Http://www.aan.com/globals/ axon/assets/9023.pdf. Accessed on February 27, 2012.
5. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-1260. (Pubitemid 38526035)
6. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-1273. (Pubitemid 38526036)
7. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-1120. (Pubitemid 44086745)
8. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: Expert opinion, 2005. Epilepsy Behav 2005;7:S1-S64. (Pubitemid 41131320)
9. Weibe S, Blume WT, Girvin JP, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001;345:311-318. (Pubitemid 32703233)
10. Engel J, Weibe S, French J, et al. Practice parameter: Temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003;60:538-547. (Pubitemid 36246066)
11. Englot DJ, Ouyang D, Garcia PA, Barbaro NM, Chang EF. Epilepsy surgery trends in the United States, 1990-2008. Neurology 2012;78:1200-1206.
12. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319. (Pubitemid 30075244)